CTLA-4 and PD-1 Antibody Combination for T-cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting CTLA-4 and PD-1 signaling have limitations in effectively enhancing immune responses for cancer treatment and infectious disease management, as they often rely on single-agent approaches that may not adequately stimulate T-cell activation.
Innovation Solution
Development of therapeutic combinations comprising antibodies specifically binding to CTLA-4 and PD-1, with defined complementarity determining regions (CDRs) in their variable regions, administered together to enhance T-cell activation and immune response, particularly for cancer and infectious disease treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent antibody therapies targeting CTLA-4 or PD-1 are used, then the treatment approach is simple and ease of manufacture is maintained, but the immune response enhancement is insufficient and T-cell activation is inadequate
Solution Approach 1:
The patent combines two different antibody therapies (anti-CTLA-4 and anti-PD-1) into a single treatment formulation. This merging of therapeutic agents allows simultaneous targeting of two distinct immune inhibition pathways, thereby enhancing overall immune response activation while maintaining a unified treatment approach that simplifies administration compared to multiple separate therapies.
2Reliability
If combination therapy with both CTLA-4 and PD-1 antibodies is administered, then T-cell activation and immune response are significantly enhanced, but the complexity of treatment administration increases
Solution Approach 1:
By formulating both anti-CTLA-4 and anti-PD-1 antibodies into a single combined therapy, the patent maintains the enhanced T-cell activation benefits of dual-pathway targeting while simplifying the administration process. The combined formulation allows for a single injection event that simultaneously engages both immune inhibition pathways, eliminating the need for separate administration events.
3Reliability
If existing single-target antibodies are used, then manufacturing and production remain straightforward, but the therapeutic effectiveness for cancer and infectious disease is limited
Solution Approach 1:
The patent merges the production and formulation of two distinct antibody therapies into a single manufactured product. This approach maintains the manufacturing capabilities for producing complex antibody formulations while enhancing therapeutic effectiveness by ensuring both anti-CTLA-4 and anti-PD-1 agents are simultaneously available in the treatment, overcoming the limitations of single-target therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of CTLA-4 and PD-1 antibodies effectively induces immune responses, enhancing T-cell activation and offering potential therapeutic benefits for cancer and infectious diseases by antagonizing immune suppression mediated by these receptors.
Implementation Method 1
antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and/or PD-1 (e.g., human PD-1)
Data Source
AI summary
Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.